Artiklar

Think Fabry, think screening at-risk family members.¹

Think Fabry, think early treatment to help slow or prevent life-threatening disease progression.^1,2

A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy.¹

Toujeo is a 2nd generation, long-acting insulin analog containing insulin glargine 300 units/mL. Toujeo® lowers blood glucose levels evenly over a long period of time. It therefore only needs to be administered once a day.

Toujeo is a 2nd generation, long-acting insulin analog containing insulin glargine 300 units/mL. Toujeo® is available in two prefilled pens. See how Toujeo® is administrated In six simple steps and watch instructional video.

Beneath the skin of patients with AD—type 2 inflammation and the cytokines involved.

Being diagnosed with type 1 diabetes at the age of 18 is a life-altering experience for most people. But when, like Lucas, you receive three other diagnoses within a few months, it can feel overwhelming. Living with type 1 diabetes becomes even more challenging when you also have autism.

Three years ago, Tina’s 13-year-old son was diagnosed with type 1 diabetes. It was a harrowing ordeal, as he was rushed to the hospital with severe diabetic ketoacidosis. Even today, the entire family remains deeply affected by the traumatic experience.

At Sanofi, our passion is to prevent, treat, and cure diseases. We are driven by the desire to improve public health and find new solutions for patients by combining science with a deep understanding of patient needs.

The Bright study demonstrated similar efficacy and safety of Toujeo^® (Glargine 300) compared to degludec (insulin degludec) in type 2 diabetes patients who had not previously received basal insulin¹.

RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2